A5044223284- Dermatology and Skin Diseases
- Neurofibromatosis and Schwannoma Cases
- Allergic Rhinitis and Sensitization
- Meningioma and schwannoma management
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Hair Growth and Disorders
- Dermatologic Treatments and Research
- Glioma Diagnosis and Treatment
- Vascular Malformations Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Head and Neck Surgical Oncology
- Contact Dermatitis and Allergies
- Ear and Head Tumors
- Pituitary Gland Disorders and Treatments
- Wound Healing and Treatments
- Chromatin Remodeling and Cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Psychology and Mental Health
- Otolaryngology and Infectious Diseases
- Biochemical and Molecular Research
Universidade José do Rosário Vellano
2024
Universidad Femenina del Sagrado Corazón
2024
Union des Industries Ferroviaires Européennes
2024
Janssen (United States)
2021-2023
Johnson & Johnson (United States)
2023
Eli Lilly (United States)
2015-2022
Massachusetts General Hospital
2003-2016
Indiana University – Purdue University Indianapolis
2016
Johns Hopkins University
2016
Guy's and St Thomas' NHS Foundation Trust
2016
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives To evaluate the efficacy safety of baricitinib patients moderate-to-severe AD who had inadequate response to therapies. Methods In two independent, multicentre, double-blind, III monotherapy trials, BREEZE-AD1 BREEZE-AD2, adults were randomized : once-daily placebo, mg, or 4 mg for 16 weeks....
Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor JAK1 and JAK2. This study tested the efficacy baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at high risk for progressive DKD.In this Phase 2, double-blind, dose-ranging study, participants were randomized 1:1:1:1:1 to receive or (0.75 mg daily; 0.75 twice 1.5 4 daily), 24 weeks followed 4-8 washout.Participants...
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) phase 3 monotherapy studies.
This is the report from fifth meeting of Harmonising Outcome Measures for Eczema initiative (HOME V). The was held on 12–14 June 2017 in Nantes, France, with 81 participants. main aims were (i) to achieve consensus over definition core domain long‐term control and how measure it (ii) prioritize future areas research measurement quality life (QoL) children. Moderated whole‐group small‐group discussions informed by presentations qualitative studies, systematic reviews validation studies....
Abstract Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations the context AD important. Baricitinib, an oral, reversible, selective inhibitor JAK1/JAK2, late‐stage development for adult patients with moderate‐to‐severe AD. Objective To report pooled data baricitinib clinical program including long‐term extension (LTE) studies. Methods This analysis included patient‐level from six double‐blinded, randomized,...
The aim of this paper was to define the clinical characteristics spinal ependymomas associated with neurofibromatosis Type 2 (NF2).The authors retrospectively reviewed records patients NF2 who had imaging findings consistent and were seen at Massachusetts General Hospital between 1994 2007. Clinical these obtained from hospital records, studies, surgical reports, pathology reports. Mutational analysis gene performed in 37 44 unrelated patients.Fifty-five met inclusion criteria for study....
Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity bevacizumab against NF2-related meningiomas, we measured changes volume NF2 who received for schwannomas. A radiographic response was defined as a 20% decrease size by volumetric MRI analysis. In addition, determined expression pattern growth factors associated with angiogenesis...
Baricitinib, an oral selective Janus kinase inhibitor, improved the clinical signs and symptoms of moderate to severe atopic dermatitis in 16-week, phase 3 monotherapy studies, BREEZE-AD1 BREEZE-AD2. Long-term efficacy has not yet been examined.To evaluate long-term (68-week) baricitinib adults with who were treatment responders or partial BREEZE-AD2.Patients completing BREEZE-AD1/BREEZE-AD2 entered ongoing, multicenter, double-blind, extension study BREEZE-AD3. The was initiated on March...
Abstract Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes psychosocial burden of AA. Methods Participants diagnosed with AA who had experienced ≥50% according to Severity Tool (SALT) were identified clinicians. A semi-structured interview guide, developed expert clinician input, included open-ended questions explore patients’ experiences living Data thematically analyzed identify concepts relationships. Results ( n = 45,...
Content‐valid and clinically meaningful instruments are required to evaluate outcomes of therapeutic interventions in alopecia areata (AA). To develop an Investigator's Global Assessment (IGA) interpret treatment response AA studies. Qualitative interviews were conducted the USA with expert dermatologists patients who had experienced ≥ 50% scalp‐hair loss. Thematic data analysis identified critical evaluated content validity new IGA. Expert clinicians (n = 10) judged success by amount growth...
The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity.To develop an AA severity scale based on expert experience.A modified Delphi process was utilized. An advisory group 22 clinical experts from the United States formed to this scale. Representatives pharmaceutical industry provided feedback during its development.Survey responses were used draft criteria, aspiring simple that may be easily applied in practice. A consensus vote held...
The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment use in clinical trials and registries atopic dermatitis (AD).To investigate the reliability, validity, responsiveness within-patient meaningful change of vIGA-AD.Data were analysed from adult patients with moderate-to-severe AD BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 615; NCT03334422) BREEZE-AD5 440; NCT03435081) phase III baricitinib studies.Across studies,...
Eyebrow and eyelash hair loss nail damage-in addition to scalp loss-are important signs/symptoms of alopecia areata (AA) patients deserve assessment in AA clinical trials.Our objective was develop clinician-reported outcome (ClinRO) patient-reported (PRO) measures accompanying photoguides aid the AA-related eyebrow, signs/symptoms.Iterative rounds qualitative, semi-structured interviews were conducted with US expert dermatologists North American AA. Patients involvement purposefully sampled....
Baricitinib, a selective Janus kinase 1/Janus 2 inhibitor, is indicated in the European Union and Japan for treatment of moderate-to-severe atopic dermatitis (AD) adults who are candidates systemic therapy. The objective this study was to evaluate safety baricitinib mg AD clinical program. Six double-blind, randomized, placebo-controlled studies, two long-term extension studies were summarized datasets. Placebo comparison based on six 16-week with mg. All-bari-2-mg-AD included patients...
Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list of validated, feasible instruments to measure atopic eczema care. Prior work identified symptoms long-term control as the most important domains practice. Patient-Oriented Measure (POEM) Scoring Atopic Dermatitis Index (PO-SCORAD) were recommended by consensus practice, but...
Background Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient's quality of life (QoL).Objective To evaluate the impact baricitinib on patient-reported outcomes (PROs) adult patients with moderate-to-severe AD, explore association between improvement key signs AD improvements QoL assessment disease severity.Methods Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) which randomized 2:1:1:1...
Neurofibromatosis 2 is a severe autosomal dominant disorder characterized by the occurrence of bilateral vestibular schwannomas and other benign tumors nervous system. Excellent natural history studies exist for adults with neurofibromatosis 2, but limited outcome data are available children 2. In this study, we present clinical on 12 patients age at diagnosis before 18 years. Full record review included surgical reports, pathology imaging studies; all were personally examined single author....
Meningiomas may occur either as familial tumors in two distinct disorders, multiple meningioma and neurofibromatosis 2 (NF2), or sporadically, single individuals with no family history. NF2 approximately 60% of sporadic meningiomas involve inactivation the locus, encoding tumor suppressor merlin on chromosome 22q. This study was undertaken to establish whether genomic profiling could distinguish from solitary meningiomas.We compared 73 presenting (64), (5) (4) using by array comparative...
BackgroundValid patient‐reported outcome (PRO) measures are required to evaluate alopecia areata (AA) treatments.